Dr. Dorff on the Continued Investigation of Upfront Chemotherapy in mHSPC
Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.
Dr. Dorff on the Exploration of Triplet Combination Therapies in mHSPC
Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.
Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC
Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.
Metastatic CRPC Management: Future Directions in Care
Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.
Dr. Dorff on Second-line Immune Checkpoint Inhibitors in Metastatic RCC
Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.
Addressing Barriers to Care in Metastatic Castration-Resistant Prostate Cancer
Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.
Metastatic CRPC: Selecting Patients for Cabazitaxel or Radiotherapy
Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.
Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC
A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.
Metastatic CRPC: Considering Use of Combination Cabazitaxel/Carboplatin
Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.
Interpreting Data From the CARD Trial in Metastatic CRPC
Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.
The PROSELICA Trial: Cabazitaxel Dosing in Metastatic CRPC
Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.
Practical Considerations for Sequencing Cabazitaxel in Metastatic CRPC
Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.
Overview on Metastatic CRPC and Available Treatment Options
Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).
Practical Considerations in Selecting Therapy for Metastatic CRPC
Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.
What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?
Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
Metastatic CRPC: Practical Selection and Use of PARP Inhibitors
Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.
An Overview of PARP Inhibition in Metastatic CRPC
Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.
PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition
Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.
Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC
A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.
Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies
Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.
Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC
Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.
Addressing Unmet Needs in Nonmetastatic CRPC
Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.
Selecting Among Available AR Inhibitors in Nonmetastatic CPRC
A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.
Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy
Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.
Clinical Scenario 2: A 64-Year-Old Man With nmCRPC
Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.
Improving Patient Monitoring in the Setting of Metastatic HSPC
Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.
Clinical Trial Data in Metastatic HSPC From the ASCO 2022 Annual Meeting
Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.
Establishing Eligibility for Frontline AR-Targeted Therapy in mHSPC
Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.
Factors in Selecting AR-Targeted Therapy for Patients With Metastatic HSPC
Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.
Optimizing Management of mHSPC: Multimodality Care and Genetic Testing
A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512